CytoMed Therapeutics (GDTC) Financial Statements & Analysis

CytoMed Therapeutics (GDTC) Income Statement

CytoMed Therapeutics reported revenue of SGD 860.85K in fiscal 2025 (fiscal year ended Dec 31, 2025), up 1138.6% from SGD 69.50K a year earlier. CytoMed Therapeutics posted a net loss of SGD 3.98M, compared with a net loss of SGD 2.52M a year earlier. Gross margin was 29.8% and operating margin -477.4%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was SGD 157.67K, up 16.9% from the same quarter a year earlier.

CytoMed Therapeutics Income Statement Analysis

Values in millions SGD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

CytoMed Therapeutics Limited income statement - Annual data in millions SGD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Mar 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Revenue & Gross Profit
Revenue	0.86	0.07	0.51	0.51	0.36	0.00	0.00	0.00
Cost of Revenue	0.09	0.02	0.00	0.00	0.01	0.00	0.00	0.00
Gross Profit	0.26	0.05	0.51	0.50	0.36	0.11	0.05	0.00
Operating Expenses
Research & Development	2.22	1.91	1.59	1.59	1.52	1.09	1.04	0.44
Selling, General & Administrative	0.99	1.27	0.49	1.28	0.40	0.59	0.15	0.04
Operating Expenses	4.37	3.18	2.08	3.84	1.86	1.27	1.18	0.65
Operating Income	-4.11	-3.13	-3.20	-3.84	-1.86	-1.16	-1.33	-0.65
Other Income/Expense
Interest Income	-0.01	0.32	0.28	0.29	0.00	0.00	0.11	0.03
Interest Expense	0.02	0.02	0.05	0.05	0.13	0.12	0.11	0.00
Other Income/Expense	0.11	0.55	-2.56	-0.52	-1.15	-0.90	-0.53	-0.21
Income
Income Before Tax	-4.00	-2.58	-4.14	-4.13	-3.13	-2.06	-1.86	-0.86
Income Tax Expense	0.00	-0.05	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-3.98	-2.52	-4.14	-4.13	-3.13	-2.07	-1.94	-0.86
Net Income - Continuous Operations	-4.00	-2.52	-4.14	-4.13	-3.13	-2.07	-1.94	-0.86
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-
EBITDA	-3.85	-1.99	-3.89	-3.70	-2.61	-1.42	-0.78	-0.47
EBIT	-4.23	-2.50	-	-4.08	-3.00	-1.74	-1.32	-
Depreciation & Amortization	0.23	0.13	0.10	0.10	0.11	0.33	0.29	0.13
Earnings Per Share
Basic EPS	-	-	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-	-	-
Basic Shares Outstanding	11.65	11.54	10.63	10.63	10.94	6.93	5.90	5.55
Diluted Shares Outstanding	11.65	11.54	10.63	10.63	10.94	6.93	5.90	5.55

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About CytoMed Therapeutics Financial Statements

What was CytoMed Therapeutics's revenue in fiscal 2025?

CytoMed Therapeutics reported revenue of SGD 860.85K in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 1138.6% from SGD 69.50K a year earlier.

Is CytoMed Therapeutics profitable?

No. CytoMed Therapeutics reported a net loss of SGD 3.98M in fiscal 2025. In fiscal 2024 it lost SGD 2.52M.

What is CytoMed Therapeutics's operating margin?

CytoMed Therapeutics's operating income was −SGD 4.11M on revenue of SGD 860.85K in fiscal 2025, an operating margin of -477.4%, compared with -4504.3% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition